Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
Pancreatic Cancer|Adjuvant Therapy
DRUG: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
18-month RFS, defined recurrence as new lesions on the basis of response evaluation criteria in solid tumours (v.1.1), and RFS from either the date of surgery (RFS) or from the date of the last neoantigen vaccine priming dose to the date of recurrence or death, whichever occurred first., through study completion, an average of 2 year|Incidence of Treatment-Related Adverse Events [Safety and Tolerability], Defined by treatment-related adverse events as assessed by CTCAE v4.0, 3 months after the last administration of neoantigen vaccine
18-month OS, defined OS from the date of surgery to the date of death., through study completion, an average of 3 year
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer